人骨形態(tài)發(fā)生蛋白-7/OP-1|Human BMP-7/OP-1
產(chǎn)品名稱: 人骨形態(tài)發(fā)生蛋白-7/OP-1|Human BMP-7/OP-1
產(chǎn)品型號(hào): C02-120-03-100ug
產(chǎn)品展商: peprotech
產(chǎn)品文檔: 無相關(guān)文檔
簡(jiǎn)單介紹
人骨形態(tài)發(fā)生蛋白-7/OP-1|Human BMP-7/OP-1系列產(chǎn)品主要適用于試驗(yàn)室或生化科研相關(guān)試驗(yàn),CANSPEC品質(zhì)提供的人骨形態(tài)發(fā)生蛋白-7/OP-1|Human BMP-7/OP-1性能**,中文名稱為人骨形態(tài)發(fā)生蛋白-7/OP-1|Human BMP-7/OP-1。產(chǎn)品人骨形態(tài)發(fā)生蛋白-7/OP-1|Human BMP-7/OP-1以其優(yōu)良的品質(zhì)滿足您不同科研實(shí)驗(yàn)的多種需求。
人骨形態(tài)發(fā)生蛋白-7/OP-1|Human BMP-7/OP-1
的詳細(xì)介紹
產(chǎn)品名稱:人骨形態(tài)發(fā)生蛋白-7/OP-1|Human BMP-7/OP-1
產(chǎn)品規(guī)格:
C02-120-03-100ug | 人骨形態(tài)發(fā)生蛋白-7/OP-1|Human BMP-7/OP-1 | 100ug | ¥23,310 |
C02-120-03-10ug | 人骨形態(tài)發(fā)生蛋白-7/OP-1|Human BMP-7/OP-1 | 10ug | ¥1,960 |
C02-120-03-1mg | 人骨形態(tài)發(fā)生蛋白-7/OP-1|Human BMP-7/OP-1 | 1mg | ¥109,200 |
C02-120-03-2ug | 人骨形態(tài)發(fā)生蛋白-7/OP-1|Human BMP-7/OP-1 | 2ug | ¥680 |
C02-120-03-500ug | 人骨形態(tài)發(fā)生蛋白-7/OP-1|Human BMP-7/OP-1 | 500ug | ¥65,520 |
單 位:瓶
關(guān) 鍵 字:人骨形態(tài)發(fā)生蛋白-7/OP-1|Human BMP-7/OP-1
CANSPEC品質(zhì)提供的人骨形態(tài)發(fā)生蛋白-7/OP-1|Human BMP-7/OP-1性能**,英文名稱人骨形態(tài)發(fā)生蛋白-7/OP-1|Human BMP-7/OP-1,簡(jiǎn)稱為人骨形態(tài)發(fā)生蛋白-7/OP-1|Human BMP-7/OP-1,中文名稱為人骨形態(tài)發(fā)生蛋白-7/OP-1|Human BMP-7/OP-1 。
產(chǎn)品人骨形態(tài)發(fā)生蛋白-7/OP-1|Human BMP-7/OP-1以其優(yōu)良的品質(zhì)滿足您不同實(shí)驗(yàn)的多種需求。并保證每批人骨形態(tài)發(fā)生蛋白-7/OP-1|Human BMP-7/OP-1的質(zhì)量和人骨形態(tài)發(fā)生蛋白-7/OP-1|Human BMP-7/OP-1品質(zhì)優(yōu)良。
English Information
Synonyms : | OP-1 |
Description : | TGF-β family members are key modulators of cell proliferation, differentiation, matrix synthesis, and apoptosis. As implied by their name, BMPs initiate, promote, and regulate the development, growth and remodeling of bone and cartilage. In addition to this role, BMPs are also involved in prenatal development and postnatal growth, remodeling and maintenance of a variety of other tissues and organs. BMP-7, also known as osteogenic protein-1 or OP-1, is a potent bone inducing agent, which in the presence of appropriate osteoconductive carrier (e.g. collagen sponge or synthetic hydroxyapatite) can be used in the treatment of bone defects. A bone-graft substitute, called OP-1TM implant, made of recombinant human BMP-7 associated with bovine bone-derived collagen, has recently been approved by the FDA as a device for treating critical-size bone fractures. The potential use of BMP-7 in dental reconstructive surgeries is currently under investigation. Recombinant human BMP-7 is a 28.8 kDa homodimeric glycoprotein consisting of two 116 amino acid subunits, which correspond to amino acid residues 316 to 431 of the full-length BMP-7 precursor. |
Catalog #: | 120-03 |
Source : | CHO cells |
Stability : | The lyophilized protein is stable for at least 2 years from date of receipt at -200C. Reconstituted BMP-7 is stable for at least 3 months when stored in working aliquots with a carrier protein at -200C. Avoid repeated freeze/thaw cycles. |
Purity : | Greater than 98% by SDS-PAGE gel and HPLC analyses. |
Endotoxin Level : | Endotoxin level is less than 0.1 ng per μg (1EU/μg). |
Biological Activity : | Determined by its ability to induce alkaline phosphatase production by ATDC-5 cells. The expected ED50 for this effect is 0.02-0.04 μg/ml. |
AA Sequence : | MANVAENSSS DQRQACKKHE LYVSFRDLGW QDWIIAPEGY AAYYCEGECA FPLNSYMNAT NHAIVQTLVH FINPETVPKP CCAPTQLNAI SVLYFDDSSN VILKKYRNMV VRACGCH |
PubMed Link : | BMP-7 |
Country of Origin : | USA |